Compare Novavax Inc (NVAX) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs uniQure N.V. Ordinary Shares — how do they compare? Novavax Inc trades at $12.4 (market cap $2.11B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Novavax Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NVAX | QURE | |
|---|---|---|
Market Cap | $2.11B | $1.48B |
Volume | 8,376,831 | 2,488,780 |
Sector | Health | Health |
52-Week High | $12.82 | $70.59 |
52-Week Low | $6.22 | $9.03 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $1.69B | $728.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.82, up 1.26% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and strategic pivots toward its Matrix-M adjuvant platform and partnerships, such as with Sanofi for COVID-19 vaccines, highlight operational progress. However, negative cash flows and a net loss in 2026 projections underscore financial volatility amid transitioning revenue streams.
The outlook balances near-term catalysts from vaccine approvals and partnership momentum against persistent cash burn and competitive pressures. Investors face opportunity in undervalued metrics like a low P/E of 3.14, but risks include execution hurdles and dependency on successful licensing deals to achieve sustainable profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
